Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...

Expert-Backed Tips For Regowing Your Hair This article was reviewed by Knox Beasley, MD. Ask the internet how to get thicker ...

Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a ...

The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of ...

Among 27 men who received 25 mL to 1.5 L of a water-like liquid known as perfluorodecalin, 20 were able to retain it within their intestines for 60 minutes, reported Takanori Takebe, MD, PhD, of the ...

Return on Assets (ROA): Vertex's financial strength is reflected in its exceptional ROA, which exceeds industry averages.

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

Tylah Tully looks at Vertex Minerals and its growing high-grade gold production in the latest episode of Stockhead's Who’s ...

The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.58 per share, up from $4.38 per share in the year-ago period. The consensus estimate for Vertex ...

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 ...